PMV Pharmaceuticals, Inc.
PMVP
$1.38
$0.042.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.62M | 15.90M | 16.33M | 18.29M | 18.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.66M | 83.66M | 86.21M | 85.51M | 84.88M |
| Operating Income | -79.66M | -83.66M | -86.21M | -85.51M | -84.88M |
| Income Before Tax | -75.20M | -78.32M | -79.91M | -84.90M | -82.99M |
| Income Tax Expenses | 23.00K | 25.00K | -2.17M | -2.20M | -2.12M |
| Earnings from Continuing Operations | -75.22 | -78.34 | -77.74 | -82.71 | -80.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.22M | -78.34M | -77.74M | -82.71M | -80.87M |
| EBIT | -79.66M | -83.66M | -86.21M | -85.51M | -84.88M |
| EBITDA | -79.54M | -83.53M | -86.07M | -85.37M | -84.40M |
| EPS Basic | -1.41 | -1.48 | -1.48 | -1.58 | -1.56 |
| Normalized Basic EPS | -0.88 | -0.93 | -0.95 | -0.94 | -0.92 |
| EPS Diluted | -1.41 | -1.48 | -1.48 | -1.58 | -1.56 |
| Normalized Diluted EPS | -0.88 | -0.93 | -0.95 | -0.94 | -0.92 |
| Average Basic Shares Outstanding | 212.91M | 211.53M | 210.16M | 208.77M | 207.35M |
| Average Diluted Shares Outstanding | 212.91M | 211.53M | 210.16M | 208.77M | 207.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |